Peridialytic Erythropoietin versus Roxadustat in Hemodialysis-Dependent Chronic Kidney Disease Patients
Peridialytic erythropoietin was associated with a more favorable cardiovascular safety profile versus roxadustat in hemodialysis-dependent CKD patients.
Authors
- Changlin Mei
- Chuan‐Ming Hao (ORCID: https://orcid.org/0000-0002-4307-0987)
- Pei Yu
- Cheng Xue (ORCID: https://orcid.org/0000-0002-4132-9406)
- Yueqi Cao (ORCID: https://orcid.org/0000-0001-8856-2902)
- Lihua Wang (ORCID: https://orcid.org/0000-0002-6198-7561)
- Yao Li (ORCID: https://orcid.org/0000-0001-5760-9421)
- Weijie Yuan
Institutions
- Fudan University (CN)
- Shanghai Changzheng Hospital (CN)
- Shanghai First People's Hospital (CN)
- First Hospital of China Medical University (CN)
- Huashan Hospital (CN)
- Tianjin Medical University (CN)
- China Medical University (CN)
Publication Details
- Journal
- American Journal of Nephrology
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1159/000546158
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00